Critical reviews of 1470-nm laser vaporization on benign prostatic hyperplasia.

Benign prostatic hyperplasia (BPH) is recognized as the common chronic disease that affect majority of men in their elder ages. Nevertheless, there are no effective documents for BPH treatment. Even though great progression has been made on BPH by laser surgery, it also faces several challenges. In this study, our aims were to explore the effects of 1470-nm laser vaporization on BPH. For the research, a total of 170 BPH patients were enrolled. A 1470-nm laser vaporization apparatus was purchased for the surgery. The indicators such as serum sodium, international prostate symptom score (IPSS), Quality of life (QOL), maximum flow rate (Qmax), prostate specific antigen (PSA), and average Post-void Residual Volume (PVR) were detected for evaluating the prostate function. The operation was successful in all 170 patients, neither of whom converted to transurethral resection of the prostate (TURP) nor to open surgery. The surgery time was 52.3 ± 5.6 min, the laser emission time was 35.6 ± 3.2 min, the energy consumption was 254.1 ± 19.3 kJ. The level of serum sodium showed no significant difference between the pre- and post-operation. Qmax was significantly increased in post-operation, while IPSS, QOL, PVR, and PSA were significantly decreased in the post-operation. The 1470-nm laser vaporization treatment protected patients against BPH, indicating that 1470-nm laser vaporization might be important on treating BPH, which provided solid foundation for further clinical treatment.

Clinical Observation of Atorvastatin Calcium Combined with Probucol in the Treatment of Atherosclerosis / 中国药房

OBJECTIVE:To investigate the clinical efficacy and safety of atorvastatin calcium combined with probucol in the treatment of atherosclerosis. METHODS:A total of 80 patients with atherosclerosis selected from the Affiliated Hospital of Sichuan College of TCM during Jan. 2015-Jan. 2016 were randomly divided into control group and observation group according to random number table,with 40 cases in each group. Control group was given Probucol tablet 0.5 g,every 2 days. Observation group was ad-ditionally given Atorvastatin calcium tablet 20 mg,qd,on the basis of control group. Both groups were treated for consecutive 24 weeks. The levels of blood lipid,arterial plaque size and thickness before and after treatment,life quality score before treatment and 3 months after treatment were observed in 2 groups;and the occurrence of ADR was recorded. RESULTS:Before treatment, there was no statistical significance in blood lipid,arterial plaque size and thickness or life quality score between 2 groups(P>0.05). After treatment,the levels of TC,TG and LDL-C,arterial plaque size and thickness in 2 groups were decreased significant-ly,while HDL-C level and life quality score were increased significantly;the improvement of above indexes in observation group was significantly better than control group,with statistical significance(P0.05). CONCLUSIONS:Atorvastatin calci-um combined with probucol in the treatment of atherosclerosis can reduce blood lipid level and get thrombolysis,and contribute to the recovery of living ability with good safety.

The application of high viscosity bone cement in treating severe osteoporotic vertebral body compression fractures / 介入放射学杂志

Objective To discuss the short-term curative effect and the safety of percutaneous vertebroplasty using high viscosity bone cement for the treatment of severe osteoporotic vertebral body compression fractures. Methods The clinical data of 100 patients with severe osteoporotic vertebral body compression fractures (compression degree>70%), who received percutaneous vertebroplasty by using high viscosity bone cement during the period from December 2010 to May 2013, were retrospectively analyzed. All the patients were followed up for at least one month. Both preoperative and postoperative visual analogue scale (VAS) and quality of life (QOL) scores, as well as the incidence of bone cement leakage, were recorded and the results were used to evaluate the curative effect and the safety of percutaneous vertebroplasty for severe osteoporotic vertebral body compression fractures. Results One week after the treatment, significant pain relief was obtained in 92 patients (92%), VAS scores decreased from preoperative (7.0 ±1.2) to postoperative (2.0±1.5), and QOL scores increased from preoperative (30±5.0) to postoperative (80±18.0);the differences were statistically significant (P0.05). Leakage of bone cement was observed in 40 patients (40%), resulting no severe neurological symptoms; among the 40 patients, intervertebral disc leakage at above and below the vertebral body was detected in 28 patients (70%), vertebral anterior edge leakage was observed in 11 patients (27.5%) and vertebral posterior edge leakage was seen in one patient (2.5%). Conclusion For the treatment of severe osteoporotic vertebral body compression fractures, percutaneous vertebroplasty by using high viscosity bone cement is safe and effective.